Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology, on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology. Read the full article: Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL)

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology. 

Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00369-0/fulltext

Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00249-0/fulltext

Antonio Uccelli (University of Genoa) discusses his research, published in the November issue of The Lancet Neurology, on the therapeutic use of mesenchymal stem cells for multiple sclerosis. Read the full article: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00301-X/fulltext

Priya Palta (Columbia University, New York) explains the importance of blood pressure control in the prevention of cognitive decline. Her Review, published in the October issue of The Lancet Neurology, provides an update of the mounting evidence that links hypertension with dementia risk. 

Adam Boxer (University of California, San Francisco) discusses his research, published in August issue of The Lancet Neurology, on diagnostic performance of tau biomarkers in neurodegenerative diseases.

Irene Cortese (National Institute of Neurological Disorders and Stroke) discusses the difficulties of designing clinical trials in progressive multifocal leukoencephalopathy and talks about a pilot study of virus-specific T cells for treatment of this population, published in the August issue of The Lancet Neurology .

Doug Turnbull (University of Newcastle) discusses mitochondrial diseases in adults, which are reviewed in the July issue of The Lancet Neurology, and explains how important these diseases are for neurologists. 

Geert Jan Biessels (University Medical Centre Utrecht) discusses his research, published in our June issue, on using strategic infarct locations to predict post-stroke cognitive impairment.

Henk-Jan Westeneng  discusses his new work on the causal effects of pre-symptomatic lifestyle on ALS .

Anne MacGregor discusses her recent Review of menstrual migraine, and explains why the problem needs greater recognition.

Peter Rothwell (Oxford University) discusses his research, found in our new issue, on asymptomatic carotid stenosis and stroke.

Professor Michael Fehlings discusses the implications of his two papers in the Jan 2021 issue of The Lancet Neurology.

Emma Jones and Simon Mead discuss their article in The Lancet Neurology, identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease.

Mark Obermann discusses his study examining the use of prednisone for the short-term prevention of cluster headache.

Robert Innis discusses his work on measuring neuroinflammation using PET imaging.

Tom Solomon discusses his Rapid Review on neurologically-associated COVID-19 problems, in The Lancet Neurology.

Huda Zoghbi discusses the prospects for future therapies in Rett syndrome.

Bas Bloem chats about his new research into a network model for reshaping chronic neurological care for patients with Parkinson's disease.

Sarah Tabrizi discusses her new research into analysing the early onset of Huntington's Disease.

Meng-Chuan Lai discusses the current evidence base for supporting autistic people.